Contact usLogin
MoleculeSalt Composition

Glimepiride 2mg + Metformin 500mg + Voglibose 0.3mg

You Searched

Voglow GM2/500/0.3mg Tablet 10s

Voglow GM2/500/0.3mg Tablet 10s

Primus Remedies Pvt. Ltd.
Strip of 10 tablets

Doctor verified video thumbnail
All Our Medicines are
who icon

WHO GMP
Certified

return Image

15 Days Easy
Returns

Long Expiry

Long Expiry
(>8 Months)

who icon

WHO GMP
Certified

return Image

15 Days Easy
Returns

Long Expiry

Long Expiry
(>8 Months)

Used In

Treatment of Type 2 diabetes mellitus

Customers also bought

More About Voglow GM

Benefits
Side Effects
How to use
How it works
What if I forget to take it?
Manufacturer Address

Benefits

Treatment of Type 2 diabetes mellitusTreatment of Type 2 diabetes mellitus

In Treatment of Type 2 diabetes mellitus Voglow 0.3 GM2 Tablet is a medicine that helps to control high blood glucose (sugar) levels. It helps to slow down the breaking down of food in our intestine to simple glucose (sugar), thereby decreasing the rise in blood glucose levels after meals. It also helps get rid of extra glucose from your body through urine. Lowering blood glucose levels is an essential part of managing diabetes. If you can control the level, you will reduce the risk of getting any of the serious complications of diabetes such as kidney damage, eye damage, nerve problems and loss of limbs. Voglow 0.3 GM2 Tablet will reduce the risk of dying from cardiovascular disease if you have type 2 diabetes and already have cardiovascular disease. Taking this medicine regularly along with proper diet and exercise will help you live a normal, healthy life. You should keep using it for as long as it is prescribed because it is protecting your future health.In Treatment of Type 2 diabetes mellitus Voglow 0.3 GM2 Tablet is a medicine that helps to control high blood glucose (sugar) levels. It helps to slow down the breaking down of food in our intestine to simple glucose (sugar), thereby decreasing the rise in blood glucose levels after meals. It also helps get rid of extra glucose from your body through urine. Lowering blood glucose levels is an essential part of managing diabetes. If you can control the level, you will reduce the risk of getting any of the serious complications of diabetes such as kidney damage, eye damage, nerve problems and loss of limbs. Voglow 0.3 GM2 Tablet will reduce the risk of dying from cardiovascular disease if you have type 2 diabetes and already have cardiovascular disease. Taking this medicine regularly along with proper diet and exercise will help you live a normal, healthy life. You should keep using it for as long as it is prescribed because it is protecting your future health.

Side Effects

The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.

How to use

Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Voglow 0.3 GM2 Tablet is to be taken empty stomach.Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Voglow 0.3 GM2 Tablet is to be taken empty stomach.

How it works

Voglow 0.3 GM2 Tablet is a combination of three antidiabetic medicines: Glimepiride, metformin and voglibose. They work by different mechanisms to provide better control of blood sugar when single or dual therapy is not effective. Glimepiride is a sulfonylurea which works by increasing the amount of insulin released by the pancreas to lower the blood glucose. Metformin is a biguanide which lowers glucose production in the liver, delays glucose absorption from intestines and increases the body's sensitivity to insulin. Voglibose is an alpha-glucosidase inhibitor which prevents breakdown of complex sugars into simple sugars such as glucose. This prevents the blood glucose levels from rising to very high levels after meals.Voglow 0.3 GM2 Tablet is a combination of three antidiabetic medicines: Glimepiride, metformin and voglibose. They work by different mechanisms to provide better control of blood sugar when single or dual therapy is not effective. Glimepiride is a sulfonylurea which works by increasing the amount of insulin released by the pancreas to lower the blood glucose. Metformin is a biguanide which lowers glucose production in the liver, delays glucose absorption from intestines and increases the body's sensitivity to insulin. Voglibose is an alpha-glucosidase inhibitor which prevents breakdown of complex sugars into simple sugars such as glucose. This prevents the blood glucose levels from rising to very high levels after meals.

Alcohol

Unsafe: Avoid consuming alcohol with Voglow 0.3 GM2 Tablet as it is deemed unsafe.Unsafe: Avoid consuming alcohol with Voglow 0.3 GM2 Tablet as it is deemed unsafe.

Pregnancy

Seek medical advice from your doctor: Voglow 0.3 GM2 Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.Seek medical advice from your doctor: Voglow 0.3 GM2 Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.

Breast feeding

Seek medical advice from your doctor: Voglow 0.3 GM2 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.Seek medical advice from your doctor: Voglow 0.3 GM2 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Driving

Caution Advised: Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.Caution Advised: Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.

Kidney

Not Safe: Voglow 0.3 GM2 Tablet is probably unsafe to use in patients with kidney disease and should be avoided. Doctor consultation is advised. Use of Voglow 0.3 GM2 Tablet is, however, not recommended in patients with severe kidney disease.Not Safe: Voglow 0.3 GM2 Tablet is probably unsafe to use in patients with kidney disease and should be avoided. Doctor consultation is advised. Use of Voglow 0.3 GM2 Tablet is, however, not recommended in patients with severe kidney disease.

Liver

Caution Advised: Voglow 0.3 GM2 Tablet should be used with caution in patients with liver disease. Dose adjustment of Voglow 0.3 GM2 Tablet may be needed. Doctor consultation is advised. Voglow 0.3 GM2 Tablet is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.Caution Advised: Voglow 0.3 GM2 Tablet should be used with caution in patients with liver disease. Dose adjustment of Voglow 0.3 GM2 Tablet may be needed. Doctor consultation is advised. Voglow 0.3 GM2 Tablet is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.

What if I forget to take it?

If a dose of Voglow 0.3 GM2 Tablet is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.If a dose of Voglow 0.3 GM2 Tablet is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.

Manufacturer Address

Primus Remedies Pvt Ltd, C-16, Ankur Cooperative Society, Thakurli Estate, Dombivili, Mumbai-421202.

Frequently asked questions

What is Voglow 0.3 GM2 Tablet?
Voglow 0.3 GM2 Tablet is a combination of Glimepiride, Metformin, and Voglibose used to treat type 2 diabetes mellitus. It helps improve blood glucose levels in adults when combined with a proper diet and exercise. Glimepiride increases insulin release, Metformin reduces liver glucose production and enhances insulin sensitivity, and Voglibose lowers post-meal glucose levels. It is not for treating Type 1 diabetes.
Can the use of Voglow 0.3 GM2 Tablet cause hypoglycemia?
Yes, Voglow 0.3 GM2 Tablet can cause hypoglycemia. Symptoms include nausea, headache, irritability, hunger, sweating, dizziness, fast heart rate, and anxiety. Risk factors include missed meals, alcohol consumption, over-exercising, or taking other antidiabetic medications. Regular blood sugar monitoring is essential, and keep glucose tablets, honey, or juice on hand.
What are the possible side effects of Voglow 0.3 GM2 Tablet?
Common side effects of Voglow 0.3 GM2 Tablet include hypoglycemia, nausea, diarrhea, altered taste, flatulence, stomach pain, headache, skin rash, and respiratory tract infections.
Is it safe to take alcohol while I am also taking Voglow 0.3 GM2 Tablet?
No, combining Voglow 0.3 GM2 Tablet with alcohol is unsafe as it may cause hypoglycemia and increase the risk of lactic acidosis.
What are the instructions for the storage and disposal of Voglow 0.3 GM2 Tablet?
Store Voglow 0.3 GM2 Tablet in its original container, tightly closed, following the storage instructions on the label. Dispose of unused medicine safely to prevent accidental ingestion by pets, children, or others.
Are there any specific conditions in which Voglow 0.3 GM2 Tablet should not be taken?
Voglow 0.3 GM2 Tablet should be avoided in patients with known allergies to its components, moderate to severe kidney disease, inflammatory bowel disease, colonic ulcerations, and metabolic acidosis, including diabetic ketoacidosis.

Checkout Editorial Policy

References

  • Glimepiride (08 Apr. 2019)

  • Metformin hydrochloride (08 Apr. 2019)

  • Dabhi AS, Bhatt NR, Shah MJ. Voglibose: An Alpha Glucosidase Inhibitor. J Clin Diagn Res. 2013;7(12):3023-7 (08 Apr. 2019)

  • Glimepiride+Metformin+Voglibose (25 Oct. 2021)

  • Metformin Hydrochloride (Prolonged Release), Voglibose & Glimepiride (28th Sept. 2023)

Disclaimer

PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.